Pfizer Buys Rights to PD-1 & VEGF Inhibitor From China Biotech

Pfizer (PFE) announced that it is in-licensing global development and commercialization rights, ex-China, to SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, from Chinese biotech, 3SBio.3SBio is already developing SSGJ-707 in China for non-small cell lung cancer (“NSCLC”), metastatic colorectal cancer, and gynecological tumors, with the first phase III study expected to begin this year.Unlike the currently available marketed products, which target only the PD-1 protein, SSGJ-707 targets two proteins ...